Cerebrovascular Diseases
Original Paper
Phenylpropanolamine and Intracranial Hemorrhage Risk in a Mexican PopulationArauz A. · Velásquez L. · Cantú C. · Nader J. · López M. · Murillo L. · Aburto Y.National Institute of Neurology and Neurosurgery ‘Manuel Velasco Suárez’, México, México
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: November 20, 2001
Accepted: July 08, 2002
Published online: March 31, 2003
Issue release date: March 2003
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 2
ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)
For additional information: https://www.karger.com/CED
Abstract
Background and Purpose: Phenylpropanolamine (PPA) has been associated with an increased risk of intracranial hemorrhage (ICH). The aim of this study was to assess the association between PPA intake and ICH in a Mexican population. Methods: We included all patients with ICH aged 18 to 51 years, with no known structural etiology, diagnosed from January 1991 to December 2000. Three to 4 controls per patient matched by sex, age (within 5 years) and place of residence were included. Patients and controls were asked about use of cold medication or appetite suppressant medications within the previous year before the interview. We considered a PPA related hemorrhage when there was a temporal relationship between the use of medication and the development of the hemorrhage, and when other causes could be ruled out. Associated risks for PPA use and other possibly related variables were estimated. Results: 177 patients (mean age 39 ± 12 years) were included; 58 (33%) were diagnosed with subarachnoid hemorrhage (SAH) and 119 (67%) with ICH. 41.2% (73 of 177) of patients had documented use of PPA within the past year and 10 (5.7%) of them had a temporal relationship between ingestion of PPA and ICH. In control subjects 42.4% (422 of 996) had been exposed to PPA and none of them developed hemorrhage. The time from PPA exposure to the onset of ICH varied from 30 minutes to 24 hours. The risk of PPA exposure for hemorrhage was not significant in cases or controls, OR 0.95 (95% CI, 0.68 to 1.34; p = 0.77). No subjects (cases or controls) reported use of PPA as an appetite suppressant. Conclusions: We found no association between ingestion of PPA and cerebral hemorrhage with respect to ingestion of PPA in the previous year. When recent use was looked at an apparent risk was evident.
© 2003 S. Karger AG, Basel
Related Articles:
References
-
Kase CS, Foster TE, Reed JE: Intracerebral hemorrhage and phenylpropanolamine use. Neurology 1987;37:399–402.
External Resources
- Weisberg L: Multiple spontaneous intracerebral hematomas; clinical and computed tomographic correlations. Neurology 1981;31:897–900.
-
Glick R, Hoying J, Cerullo L: Phenylpropanolamine: an over-the-counter drug causing central nervous system vasculitis and intracerebral hemorrhage. Case report and review. Neurosurgery 1987;20:969–972.
External Resources
-
Mueller SM: Phenylpropanolamine, a nonprescription drug with potentially fatal side effects (letter). N Engl J Med 1983;308:653.
-
Barinagarrementeria F, Méndez A, Vega F: Hemorragia cerebral asociada al uso de fenilpropanolamina. Neurología 1990;5:292–294.
External Resources
-
Bernstein E, Diskant BM: Phenylpropanolamine: a potentially hazardous drug. Ann Emerg Med 1982;11:311–313.
External Resources
- Fallis RJ, Fisher M: Cerebral vasculitis and hemorrhage associated with phenylpropanolamine. Neurology 1985;35:405–408.
-
Kikta DG, Devereaux MX, Chandar K: Intracranial hemorrhages due to phenylpropanolamine. Stroke 1985;16:510–513.
External Resources
- Stoessl AJ, Young GB, Feasby TE: Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics. Stroke 1985;16:734–737.
- Lake CR, Gallant S, Masson E, Miller P: Adverse drug effects attributed to phenylpropanolamine: A review of 142 cases reports. Am J Med 1990;89:195–208.
-
Johnson DA, Etters HS, Reeves DM: Stroke and phenylpropanolamine use. Lancet 1983;56:970–973.
-
Jick H, Aselton P, Hunter JR: Phenylpropanolamine and cerebral haemorrhage. Lancet 1984;1071:345–348.
-
McDowell JR, Le Blanc HJ: Phenylpropanolamine and cerebral hemorrhage. West J Med 1985;142:688–691.
External Resources
-
Maher LM: Postpartum intracranial hemorrhage and phenylpropanolamine use. Neurology 1987;37:1686–1688.
External Resources
-
Traynelis VC, Brick JF: Phenylpropanolamine and vasoespasm. Neurology 1986;36:593–595.
External Resources
- Kernan W, Viscoli C, Brass L, Broderick J, Brott T, Feldmann E, Morgenstern L, et al: Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343:1826–1832.
- Del Brutto O, Mosquera A, Sánchez X, Santos J, Noboa CA: Stoke subtypes among hispanics living in Guayaquil, Ecuador. Stroke 1993;24:1833–1836.
Article / Publication Details
Received: November 20, 2001
Accepted: July 08, 2002
Published online: March 31, 2003
Issue release date: March 2003
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 2
ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)
For additional information: https://www.karger.com/CED
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
